お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
958929

拡張型心筋症治療の世界市場

Dilated Cardiomyopathy Therapeutics

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 137 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

拡張型心筋症治療の世界市場
出版日: 2020年09月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 137 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の拡張型心筋症治療の市場規模は、分析期間(2020年~2027年)に4.4%のCAGRで成長する見通しで、2020年の3億450万米ドルから2027年には4億1,160万米ドルに達すると予測されています。当レポートで分析されているセグメントの1つであるアルドステロン拮抗薬は、分析期間中に3.7%の年率で成長し、408億米ドルに達すると予測されています。

当レポートは、世界の拡張型心筋症治療市場について調査しており、市場シェア、動向や見通し、成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

調査対象企業の例

  • Array BioPharma, Inc.
  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Vericel Corporation

目次

I. イントロダクション、調査手法、調査範囲

II. エグゼクティブサマリー

  • 市場概要
    • 競合の市場シェア
    • 競合の市場シェアシナリオ
    • Covid-19の影響と迫り来る世界の景気後退
  • 主要企業
  • 動向と成長要因
  • 世界市場の見通し

III. 市場分析

  • 地域別市場分析
  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

IV. 競合

  • 企業プロファイル:47社
目次
Product Code: MCP15813

Global Dilated Cardiomyopathy Therapeutics Market to Reach $411.6 Million by 2027

Amid the COVID-19 crisis, the global market for Dilated Cardiomyopathy Therapeutics estimated at US$304.5 Million in the year 2020, is projected to reach a revised size of US$411.6 Million by 2027, growing at a CAGR of 4.4% over the analysis period 2020-2027. Aldosterone Antagonists, one of the segments analyzed in the report, is projected to record a 3.7% CAGR and reach US$40.8 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Angiotensin-Converting Enzyme (ACE) Inhibitors segment is readjusted to a revised 3.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $89.7 Million, While China is Forecast to Grow at 4.2% CAGR

The Dilated Cardiomyopathy Therapeutics market in the U.S. is estimated at US$89.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$72.9 Million by the year 2027 trailing a CAGR of 4.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.2% and 3.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Angiotensin II Receptor Blockers (ARBs) Segment to Record 5% CAGR

In the global Angiotensin II Receptor Blockers (ARBs) segment, USA, Canada, Japan, China and Europe will drive the 5.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$112.5 Million in the year 2020 will reach a projected size of US$160.3 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$45.8 Million by the year 2027.We bring years of research experience to this 6th edition of our report. The 137-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

  • Array BioPharma, Inc.
  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Vericel Corporation

TABLE OF CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Global Competitor Market Shares
    • Dilated Cardiomyopathy Therapeutics Competitor Market Share Scenario Worldwide (in %): 2019 & 2025
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: Dilated Cardiomyopathy Therapeutics Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2020-2027
    • TABLE 2: Dilated Cardiomyopathy Therapeutics Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2012-2019
    • TABLE 3: Dilated Cardiomyopathy Therapeutics Market Share Shift across Key Geographies Worldwide: 2012 VS 2020 VS 2027
    • TABLE 4: Aldosterone Antagonists (Drug Class) World Market by Region/Country in US$ Thousand: 2020 to 2027
    • TABLE 5: Aldosterone Antagonists (Drug Class) Historic Market Analysis by Region/Country in US$ Thousand: 2012 to 2019
    • TABLE 6: Aldosterone Antagonists (Drug Class) Market Share Breakdown of Worldwide Sales by Region/Country: 2012 VS 2020 VS 2027
    • TABLE 7: Angiotensin-Converting Enzyme (ACE) Inhibitors (Drug Class) Potential Growth Markets Worldwide in US$ Thousand: 2020 to 2027
    • TABLE 8: Angiotensin-Converting Enzyme (ACE) Inhibitors (Drug Class) Historic Market Perspective by Region/Country in US$ Thousand: 2012 to 2019
    • TABLE 9: Angiotensin-Converting Enzyme (ACE) Inhibitors (Drug Class) Market Sales Breakdown by Region/Country in Percentage: 2012 VS 2020 VS 2027
    • TABLE 10: Angiotensin II Receptor Blockers (ARBs) (Drug Class) Geographic Market Spread Worldwide in US$ Thousand: 2020 to 2027
    • TABLE 11: Angiotensin II Receptor Blockers (ARBs) (Drug Class) Region Wise Breakdown of Global Historic Demand in US$ Thousand: 2012 to 2019
    • TABLE 12: Angiotensin II Receptor Blockers (ARBs) (Drug Class) Market Share Distribution in Percentage by Region/Country: 2012 VS 2020 VS 2027
    • TABLE 13: Beta-Blockers (Drug Class) World Market Estimates and Forecasts by Region/Country in US$ Thousand: 2020 to 2027
    • TABLE 14: Beta-Blockers (Drug Class) Market Historic Review by Region/Country in US$ Thousand: 2012 to 2019
    • TABLE 15: Beta-Blockers (Drug Class) Market Share Breakdown by Region/Country: 2012 VS 2020 VS 2027

III. MARKET ANALYSIS

  • GEOGRAPHIC MARKET ANALYSIS
  • UNITED STATES
    • Market Facts & Figures
    • US Dilated Cardiomyopathy Therapeutics Market Share (in %) by Company: 2019 & 2025
    • Market Analytics
    • TABLE 16: United States Dilated Cardiomyopathy Therapeutics Market Estimates and Projections in US$ Thousand by Drug Class: 2020 to 2027
    • TABLE 17: Dilated Cardiomyopathy Therapeutics Market in the United States by Drug Class: A Historic Review in US$ Thousand for 2012-2019
    • TABLE 18: United States Dilated Cardiomyopathy Therapeutics Market Share Breakdown by Drug Class: 2012 VS 2020 VS 2027
  • CANADA
    • TABLE 19: Canadian Dilated Cardiomyopathy Therapeutics Market Estimates and Forecasts in US$ Thousand by Drug Class: 2020 to 2027
    • TABLE 20: Canadian Dilated Cardiomyopathy Therapeutics Historic Market Review by Drug Class in US$ Thousand: 2012-2019
    • TABLE 21: Dilated Cardiomyopathy Therapeutics Market in Canada: Percentage Share Breakdown of Sales by Drug Class for 2012, 2020, and 2027
  • JAPAN
    • TABLE 22: Japanese Market for Dilated Cardiomyopathy Therapeutics: Annual Sales Estimates and Projections in US$ Thousand by Drug Class for the Period 2020-2027
    • TABLE 23: Dilated Cardiomyopathy Therapeutics Market in Japan: Historic Sales Analysis in US$ Thousand by Drug Class for the Period 2012-2019
    • TABLE 24: Japanese Dilated Cardiomyopathy Therapeutics Market Share Analysis by Drug Class: 2012 VS 2020 VS 2027
  • CHINA
    • TABLE 25: Chinese Dilated Cardiomyopathy Therapeutics Market Growth Prospects in US$ Thousand by Drug Class for the Period 2020-2027
    • TABLE 26: Dilated Cardiomyopathy Therapeutics Historic Market Analysis in China in US$ Thousand by Drug Class: 2012-2019
    • TABLE 27: Chinese Dilated Cardiomyopathy Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2012, 2020, and 2027
  • EUROPE
    • Market Facts & Figures
    • European Dilated Cardiomyopathy Therapeutics Market: Competitor Market Share Scenario (in %) for 2019 & 2025
    • Market Analytics
    • TABLE 28: European Dilated Cardiomyopathy Therapeutics Market Demand Scenario in US$ Thousand by Region/Country: 2020-2027
    • TABLE 29: Dilated Cardiomyopathy Therapeutics Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2012-2019
    • TABLE 30: European Dilated Cardiomyopathy Therapeutics Market Share Shift by Region/Country: 2012 VS 2020 VS 2027
    • TABLE 31: European Dilated Cardiomyopathy Therapeutics Market Estimates and Forecasts in US$ Thousand by Drug Class: 2020-2027
    • TABLE 32: Dilated Cardiomyopathy Therapeutics Market in Europe in US$ Thousand by Drug Class: A Historic Review for the Period 2012-2019
    • TABLE 33: European Dilated Cardiomyopathy Therapeutics Market Share Breakdown by Drug Class: 2012 VS 2020 VS 2027
  • FRANCE
    • TABLE 34: Dilated Cardiomyopathy Therapeutics Market in France by Drug Class: Estimates and Projections in US$ Thousand for the Period 2020-2027
    • TABLE 35: French Dilated Cardiomyopathy Therapeutics Historic Market Scenario in US$ Thousand by Drug Class: 2012-2019
    • TABLE 36: French Dilated Cardiomyopathy Therapeutics Market Share Analysis by Drug Class: 2012 VS 2020 VS 2027
  • GERMANY
    • TABLE 37: Dilated Cardiomyopathy Therapeutics Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Drug Class for the Period 2020-2027
    • TABLE 38: German Dilated Cardiomyopathy Therapeutics Historic Market Analysis in US$ Thousand by Drug Class: 2012-2019
    • TABLE 39: German Dilated Cardiomyopathy Therapeutics Market Share Breakdown by Drug Class: 2012 VS 2020 VS 2027
  • ITALY
    • TABLE 40: Italian Dilated Cardiomyopathy Therapeutics Market Growth Prospects in US$ Thousand by Drug Class for the Period 2020-2027
    • TABLE 41: Dilated Cardiomyopathy Therapeutics Historic Market Analysis in Italy in US$ Thousand by Drug Class: 2012-2019
    • TABLE 42: Italian Dilated Cardiomyopathy Therapeutics Market by Drug Class: Percentage Breakdown of Sales for 2012, 2020, and 2027
  • UNITED KINGDOM
    • TABLE 43: United Kingdom Market for Dilated Cardiomyopathy Therapeutics: Annual Sales Estimates and Projections in US$ Thousand by Drug Class for the Period 2020-2027
    • TABLE 44: Dilated Cardiomyopathy Therapeutics Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Drug Class for the Period 2012-2019
    • TABLE 45: United Kingdom Dilated Cardiomyopathy Therapeutics Market Share Analysis by Drug Class: 2012 VS 2020 VS 2027
  • REST OF EUROPE
    • TABLE 46: Rest of Europe Dilated Cardiomyopathy Therapeutics Market Estimates and Forecasts in US$ Thousand by Drug Class: 2020-2027
    • TABLE 47: Dilated Cardiomyopathy Therapeutics Market in Rest of Europe in US$ Thousand by Drug Class: A Historic Review for the Period 2012-2019
    • TABLE 48: Rest of Europe Dilated Cardiomyopathy Therapeutics Market Share Breakdown by Drug Class: 2012 VS 2020 VS 2027
  • ASIA-PACIFIC
    • TABLE 49: Dilated Cardiomyopathy Therapeutics Market in Asia-Pacific by Drug Class: Estimates and Projections in US$ Thousand for the Period 2020-2027
    • TABLE 50: Asia-Pacific Dilated Cardiomyopathy Therapeutics Historic Market Scenario in US$ Thousand by Drug Class: 2012-2019
    • TABLE 51: Asia-Pacific Dilated Cardiomyopathy Therapeutics Market Share Analysis by Drug Class: 2012 VS 2020 VS 2027
  • REST OF WORLD
    • TABLE 52: Rest of World Dilated Cardiomyopathy Therapeutics Market Estimates and Forecasts in US$ Thousand by Drug Class: 2020 to 2027
    • TABLE 53: Rest of World Dilated Cardiomyopathy Therapeutics Historic Market Review by Drug Class in US$ Thousand: 2012-2019
    • TABLE 54: Dilated Cardiomyopathy Therapeutics Market in Rest of World: Percentage Share Breakdown of Sales by Drug Class for 2012, 2020, and 2027

IV. COMPETITION

  • Total Companies Profiled: 47
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.